Rapid Molecular Test for Flu and COVID-19 Gets FDA Clearance and CLIA-Waiver
The point-of-care platform with multifunctional capabilities provides results in as little as 15 minutes.
Latest Articles
Editor's Top Picks
Ordering Both ESR and CRP Tests Could Save Hospitals Nearly $10 Million Per Year, Study Finds
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Nucleosome Levels Found Elevated in Trauma Patients at Risk for Blood Clots, Mayo Clinic Study Shows
A Mayo Clinic study of 674 trauma patients found elevated circulating nucleosome levels in those who developed venous thromboembolism, suggesting a potential new biomarker for early VTE risk identification.
Equipment & Supply Spotlight
12 Life Science Startups Named to SLAS Europe 2026 Innovation Showcase Program
Emerging companies from six countries will exhibit enabling technologies at the Society of Laboratory Automation and Screening's annual European conference in Vienna this May.
News, Know-How & Standards
Disease Detection & Understanding
FDA Grants CLIA Waiver for Rapid Test That Differentiates Bacterial and Non-Bacterial Respiratory Infections
The FDA has granted a CLIA waiver for FebriDx, enabling its use in over 300,000 U.S. point-of-care settings and potentially reaching 80 million patients annually, according to PHASE Scientific.
